HOME PAGE
  NEWS
  PUBLICATIONS
  COMPANY OVERVIEW
  THERAPEUTIC APPLICATIONS
  REFERENCES
  PRODUCTS

RESERVED AREA
REGISTER

 


 
Founded in October 2005 by Patrizia d´Alessio, MD PhD - AISA Therapeutics is dedicated to the development and commercialization of anti-inflammatory / anti-senescence drugs, based on a novel concept.

Mission :
AISA Therapeutics aims at developing pharmacological products which modulate the inflammation pathways.

Target :
AISA Therapeutics targets organ-specific vascular-endothelium based pathologies, such as chronic inflammatory diseases, which may develop in gastro-intestinal, joint or cardiovascular clinical settings. AISA Therapeutics molecules have also been validated for their anti-stress effects. Hence, AISA Therapeutics is cooperating with licensing partners as new drugs for human and animal health will be developed in two main indications:
  • in human health: inflammation resulting from stress; skin frailty in the elderly; dermatitis and colitis;
  • in animal health: stress and inflammatory syndromes.
Moreover, AISA molecules are naturally occurring entities present in edible plants (food) and not toxic, thus allowing a nutraceutical approach for all indications mentioned.

Innovation :
AISA molecules are non-toxic, have an anti-inflammatory effect and display anti-senescence activity.


  AISA Therapeutics
Headquarters 4, rue Pierre Fontaine - 91058 - Evry (F)
Postal address Biopark Campus Cancer 1, mail du Pr Georges Mathé 94807 - Villejuif (F)
Tel. +33.6.87.47.80.32 · Fax. +33.1.78.40.04.38 · email: info@aisa-tx.com